Expands leadership team with seasoned commercial executive
EMERYVILLE, Calif. (December 6, 2017) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces the appointment of Lewis J. Stuart as Chief Commercial Officer. Mr. Stuart joined NovaBay on December 1 and brings more than 30 years of biopharmaceutical industry experience. At NovaBay, he will be responsible for leading all commercial activities, including driving sales and revenue growth of Avenova in new and existing markets, and expanding the Company’s global commercial channel
“Lewis is a results-driven executive with extensive experience in successfully launching and growing major medical products, making him an ideal fit for this position,” said Mark Sieczkarek, NovaBay’s President and CEO. “He joins us with a track record of launching first-in-class products, a focus on maximizing productivity and strategic insights. We look for Lewis to make impactful contributions to our commercial organization as we focus on accelerating sales growth of Avenova, and welcome him to our Company.”
“Avenova offers multiple important benefits to a large and relatively untapped segment of the ophthalmology market,” commented Mr. Stuart. “I am delighted to join the NovaBay team and look forward to leading the commercial operations and driving Avenova’s ongoing success.”
Prior to NovaBay, Mr. Stuart was Vice President, U.S. Oncology for Genomic Health, where he led the marketing, sales, and medical affairs teams for their oncology franchise. He was also a member of the Board of Directors for Linkage Biosciences, Inc. recently acquired by Thermo Fisher, Inc.
Previously, he served as President and General Manager of Genetic Technologies, a women’s health/oncology company, where he established a U.S.-based molecular diagnostics division. He has also held leadership positions as Senior Vice President, Commercial Operations at CV Therapeutics, a Gilead Sciences acquisition, and Vice President, Sales & Community Marketing at Agouron Pharmaceuticals, before its acquisition by Pfizer, Inc.
Mr. Stuart holds a BA in Communications & Marketing Management from Virginia Polytechnic and State University.
Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding any potential benefit or deleterious effect due to the transition in management, inclusive of any possible effect that would have generally on the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company’s intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
From the Company
Chief Financial Officer